Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer

2014 Tzeng, 2013, Colorectal liver metastases, J Gastrointest Surg, 17, 195, 10.1007/s11605-012-2022-3 Shimizu, 2007, Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience, Int J Clin Oncol, 12, 218, 10.1007/s10147-007-0658-x Schmoll, 2012, The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (CAPOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (CAPOXA), J Clin Oncol, 30, 3578, 10.1200/jco.2012.30.15_suppl.3578 Madi, 2012, Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial, Br J Cancer, 107, 1037, 10.1038/bjc.2012.384 Schmoll, 2014, Lancet Oncol, 15, 1481, 10.1016/S1470-2045(14)70486-3 Andre, 2009, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J Clin Oncol, 27, 3109, 10.1200/JCO.2008.20.6771 Andre, 2004, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 350, 2343, 10.1056/NEJMoa032709 Schmoll, 2007, Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients, J Clin Oncol, 25, 102, 10.1200/JCO.2006.08.1075 Smith, 2011, Bending the cost curve in cancer care, N Engl J Med, 364, 2060, 10.1056/NEJMsb1013826 Maroun, 2003, Lifetime costs of colon and rectal cancer management in Canada, Chronic Dis Can, 24, 91 Perrocheau, 2010, Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: CAPOX versus FOLFOX-6, Oncology, 79, 174, 10.1159/000325999 Shiroiwa, 2009, Cost-effectiveness analysis of CAPOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials, Br J Cancer, 101, 12, 10.1038/sj.bjc.6605114 Tse, 2011, Cost-analysis of CAPOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement, BMC Cancer, 11, 288, 10.1186/1471-2407-11-288 2006 Vera-Llonch, 2011, Healthcare costs in patients with metastatic lung cancer receiving chemotherapy, BMC Health Serv Res, 11, 305, 10.1186/1472-6963-11-305 Warren, 2008, Evaluation of trends in the cost of initial cancer treatment, J Natl Cancer Inst, 100, 888, 10.1093/jnci/djn175 Cassidy, 2011, CAPOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results, Br J Cancer, 105, 58, 10.1038/bjc.2011.201 Aitini, 2012, Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer, Cancer Manag Res, 4, 99 Xie, 2013, Cost analysis of adjuvant therapy with CAPOX or FOLFOX4 for colon cancer, Colorectal Dis, 15, 958, 10.1111/codi.12216 Chu, 2014, Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial, Br J Cancer, 110, 1438, 10.1038/bjc.2014.74 Eggington, 2006, Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer, Br J Cancer, 95, 1195, 10.1038/sj.bjc.6603348 Ward, 2003, Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation, Health Technol Assess, 7, 1, 10.3310/hta7320 Bodrogi, 2010, Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development, Br J Pharmacol, 159, 1367, 10.1111/j.1476-5381.2009.00550.x